Profile Of Patients With Advanced Parkinson’s disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients

Figures & data

Table 1 Characterization Of Patients With APD

	Fully Evaluated APD Patients N=286	Suitable For DAT n=125	Conservative Treatment (CONS) n=161	p (DAT vs CONS)
Male (n, %)	147 (51.4%)	65 (52%)	82 (51%)	ns
Average age (years±SD)
All patients	69.1±9.0	65.1±8.8	72.1±8.0	<0.0001
Male	68.3±9.5	65.0±9.5	71.0±8.7	<0.0001
Female	69.9±8.5	65.5±8.2	73.2±7.1	<0.0001
Time since PD diagnosis (average±SD)	9.1±3.8	11.1±4.3	7.6±2.3	<0.0001
MMSE (average±SD)	25.00±2.7	24.99±2.3	25.01±3.0	ns
Hoehn–Yahr Scale
On state (average±SD)	3.19±0.4	3.34±0.5	3.07±0.3	<0.0001
Off state (average±SD)	4.26±0.4	4.5±0.5	4.1±0.3	<0.0001
Average off duration (hours, average±SD)	3.62±1.3	4.7±1.1	2.8±0.8	<0.0001
Off duration (years, average±SD)	4.0±2.7	5.8±2.8	2.6±1.4	<0.0001
Dyskinesia (n)	110	83	27	<0.0001
Duration (hours, average±SD)	2.7±0.9	3.0±0.8	1.8±0.6	<0.0001
Duration (years, average±SD)	3.5±2.2	4.1±2.2	1.7±1.0	<0.0001
Dystonia (n)	27	23	4	<0.0001
Duration (hours, average±SD)	1.5±0.7	1.5±0.7	1.4±0.5	ns
Duration (years, average±SD)	2.3±1.4	2.5±1.4	1.25±0.5	p=0.04
Early morning akinesia (n)	188	118	70	<0.0001
Duration (years, average±SD)	2.31±1.5	2.8±1.7	1.6±0.8	<0.0001
Freezing (n)	93	80	13	<0.0001
Duration (hours, average±SD)	2.0±0.9	2.0±0.9	1.7±0.9	ns
Levodopa
Average dose (mg/day)	680.9±207.4	753.8±240.4	624.2±156.3	<0.0001
Median dose (mg/day)	600	750	600
Daily dosage frequency (mean±SEM)	4	5.0±0.09	4.1±0.02	<0.0001
Combined treatment (n/N, %)
DAs	215/286 (75%)	99/125 (79%)	116/161 (72%)	p=0.17
MAO-Bi	181/286 (63%)	85/125 (68%)	96/161 (60%)	p=0.17
Amantadine	54/286 (19%)	42/125 (34%)	12/161 (7%)	<0.0001
Entacapone	164/286 (57%)	87/125 (70%)	77/161 (48%)	<0.001

Abbreviations: PD, Parkinson’s disease; APD, advanced Parkinson’s disease; DAT, Device-aided therapies; LCIG, levodopa-carbidopa intestinal gel; SD, standard deviation; SEM, standard error of mean; DAs, dopamine agonists; LD, levodopa; MAO-Bi, monoamine oxidase B inhibitor.

Figure 1 Flowchart of clinical decision-making.